Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

Published:2016-03 Issue:3 Volume:29 Page:270-284
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Smith Michael P.,Brunton Holly,Rowling Emily J.,Ferguson Jennifer,Arozarena Imanol,Miskolczi Zsofia,Lee Jessica L.,Girotti Maria R.,Marais Richard,Levesque Mitchell P.,Dummer Reinhard,Frederick Dennie T.,Flaherty Keith T.,Cooper Zachary A.,Wargo Jennifer A.,Wellbrock Claudia

Funder

Cancer Research UK

AICR

Wellcome Trust

NIH

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference45 articles.

1. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3;Abel;J. Clin. Invest.,2013

2. The causes and consequences of genetic heterogeneity in cancer evolution;Burrell;Nature,2013

3. Genomic classification of cutaneous melanoma;Cancer Genome Atlas Network;Cell,2015

4. SKI knockdown inhibits human melanoma tumor growth in vivo;Chen;Pigment Cell Melanoma Res.,2009

5. Anti-HIV drugs for cancer therapeutics: back to the future?;Chow;Lancet Oncol.,2009

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib);Cell Communication and Signaling;2024-08-23

2. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma;Molecular Cancer;2024-07-04

3. Purinergic Ca2+ Signaling as a Novel Mechanism of Drug Tolerance in BRAF-Mutant Melanoma;Cancers;2024-06-30

4. Identification of BRAF Inhibitor Resistance–associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening;Anticancer Research;2024-05-31

5. MiR-29 and MiR-140 regulate TRAIL-induced drug tolerance in lung cancer;Animal Cells and Systems;2024-04-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3